- Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
- Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
- Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
- Thelaziasis
- My Father’s Code
- Abortion Care in Puerto Rico — A Fragile Legal Landscape
- The Future of Health Agency Enforcement Fines
- Targeting HER2 — A Triumph of Science
- Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
- Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
- Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
- Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion
- Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke
- Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke
- Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy
